このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Atai Life Sciences 過去の業績

過去基準チェック /06

Atai Life Sciencesは10.7%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はdecliningで0.4%毎年増加している。売上は減少しており、年平均121.6%の割合である。

主要情報

10.7%

収益成長率

35.0%

EPS成長率

Pharmaceuticals 業界の成長	6.0%
収益成長率	-121.6%
株主資本利益率	-16.5%
ネット・マージン	-12,202.9%
前回の決算情報	31 Mar 2024

Recent updates

ATAI: Enormous Potential Upside But No Clarity Yet

May 27

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?

Mar 02

atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug

Oct 12

収支内訳

Atai Life Sciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGM:ATAI 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Mar 24	0	-34	61	54
31 Dec 23	0	-40	62	60
30 Sep 23	0	-67	58	68
30 Jun 23	0	-145	64	74
31 Mar 23	0	-149	65	76
31 Dec 22	0	-152	70	74
30 Sep 22	0	-196	81	65
30 Jun 22	1	-194	81	60
31 Mar 22	0	-205	101	58
31 Dec 21	20	-168	93	48
30 Sep 21	20	-166	139	38
30 Jun 21	20	-218	123	33
31 Mar 21	20	-185	88	15
31 Dec 20	0	-170	81	11

質の高い収益: ATAIは現在利益が出ていません。

利益率の向上: ATAIは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ATAIは利益を出していないが、過去 5 年間で年間10.7%の割合で損失を削減してきた。

成長の加速: ATAIの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ATAIは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 19.9% ) と比較することは困難です。

株主資本利益率

高いROE: ATAIは現在利益が出ていないため、自己資本利益率 ( -16.54% ) はマイナスです。

Atai Life Sciences 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.21 loss in 1Q 2023)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Atai Life Sciences N.V. to Report Q3, 2022 Results on Nov 10, 2022

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.37 loss in 2Q 2021)

Recent updates

Atai Life Sciences Announces Update on Beckley Psytech’S Phase 1/2A Trial of Ele-101 (Iv Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2A

ATAI: Enormous Potential Upside But No Clarity Yet

Atai Life Sciences N.V. Announces Board and Supervisory Board Changes

Co-Founder recently sold US$291k worth of stock

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.21 loss in 1Q 2023)

Atai Life Sciences N.V. Announces CEO Changes

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Atai Life Sciences N.V., Annual General Meeting, May 17, 2024

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Co-Founder & Chief Scientific Officer recently sold US$114k worth of stock

Price target decreased by 19% to US$11.80

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

Price target increased by 18% to US$14.50

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?

atai Life Sciences Announces Management Changes

Atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)

Atai Life Sciences N.V. (NasdaqGM:ATAI) acquired remaining stake of DemeRx IB, Inc.

Atai Life Sciences N.V. (NasdaqGM:ATAI) acquired remaining stake of DemeRx IB, Inc.

Atai Life Sciences N.V. Announces Executive Changes

Atai Life Sciences N.V. Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

Co-Founder & CEO recently bought US$58k worth of stock

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates decrease by 48%, EPS upgraded

atai Life Sciences Announces Results from the Phase 1 Iv-To-Subcutaneous Bridging Study of Pcn-101 (R-Ketamine)

Consensus revenue estimates increase by 19%

Co-founder & CEO recently bought US$104k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of Grx-917

Atai Life Sciences Announces Results from Phase 2A Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

Price target decreased to US$20.97

598 Initiates Phase 2B Proof-Of-Concept Trial of Rl-007 for Cognitive Impairment Associated with Schizophrenia

Atai Life Sciences Appoints Sahil V. Kirpekar as Chief Business Officer

Atai Life Sciences N.V. and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment

Consensus forecasts updated

Consensus forecasts updated

Alexis De Rosnay Resigns as a Member of the Supervisory Board of Directors of Atai Life Sciences N.V

Atai Life Sciences N.V. to Report Q3, 2022 Results on Nov 10, 2022

Atai Life Sciences and Perception Neuroscience Completes Enrollment for Phase 2A Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

Atai Life Sciences N.V. Announces Initiation of Phase 1 Proof-Of-Concept Clinical Trial for Its Sol-Gel Based Direct-To-Brain Drug Delivery Technology

Atai Life Sciences N.V. Appoints Stephen Bardin as Managing Director

Atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD

atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug

Atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and Iv Vls-01, A Synthetic Form of Dmt

Atai Life Sciences: Decentralized Drug Discovery Platform

atai Life Sciences N.V. Announces Initiation of Phase 1 Trial for Its MDMA Derivative, EMP-01

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.37 loss in 2Q 2021)

ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01

We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Atai Life Sciences N.V. to Report Q2, 2022 Results on Aug 15, 2022

Price target decreased to US$23.72

Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer

atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO

Atai Life Sciences N.V. Announces Executive Changes

Atai Life Sciences N.V.: A First Take

Atai Life Sciences And The Future Of Psychedelics For Mental Health

Atai Life Sciences N.V. to Report Q1, 2022 Results on May 16, 2022

Atai Life Sciences N.V., Annual General Meeting, May 25, 2022

We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

atai Life Sciences N.V. Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments

Atai Life Sciences Announces Fda Investigational New Drug Clearance for Pcn-101 R-Ketamine Program

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia

Atai Life Sciences N.V. Announces the Launch of TryptageniX